Telmisartan (MICARDIS(R)) as Effective as Ramipril But With Better Long-Term Tolerability in High-Risk Cardiovascular As

    
    Related links:
    http://www.news-ontarget.com
    http://www.ontarget-telmisartan.com
    http://www.micardis.com

References

(1) Dans A. Tolerance of telmisartan and ramipril amongst Asians - The ONTARGET Trial. Presented at the 19th Great Wall International Congress of Cardiology, Beijing, China, 23 October 2008.

(2) The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Eng J Med 2008; 358(15):1547-59.

(3) Israili ZH, Hall WD. Cough and angioedema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117(3):234-42.

(4) Matchar DB, et al. Systematic Review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148:16-29.

(5) Macaulay TE, Dunn SP. Cross-reactivity of ACE-inhibitor-induced angioedema with ARBs. US Pharmacist 2007; 32(2).

(6) Woo J, Chan TY. A high incidence of cough associated with combination therapy of hypertension with isradipine and lisinopril in Chinese subjects. B J Clin Pract 1991; 45(3):178-80.

(7. Woo KS, Norris R, Nicholls G. Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors. Am J Cardiol. 1995; 75(14):967-8.

(8) The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet8 2008; 372:1174-118.

(9) .World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007. http://www.who.int/mediacentre/factsheet... (Accessed August 2008).

(10) Lawes CM et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21(4):673-5.

(11) World Health Organization, The Atlas of Heart Disease and Stroke 2004. http://www.who.int/cardiovascular_diseas... Accessed October 2008.

(12) Murray CJL, Lopez AD. eds. The Global Burden of Disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge; Harvard University Press 2001.

Contact: Dr. Reinhard Malin, Corporate Division Communications, Boehringer Ingelheim GmbH, 55216 Ingelheim/Germany, Phone: + 49-6132-77-97296, 77-90815, Fax: + 49-6132-72-6601, E-mail: press@boehringer-ingelheim.com